Sangamo to Highlight Genomic Medicine Pipeline, Technology Platforms, and Manufacturing Capabilities in December 17 R&D Day – Associated Press


Press release content from Business Wire. The AP news staff was not involved in its creation.

BRISBANE, Calif.–(BUSINESS WIRE)–Dec 6, 2019–

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the Company plans to host an R&D Day on December 17, 2019 at 8am Eastern Time in New York City. Sangamo executives and scientists will provide updates across the Company’s clinical and preclinical pipeline of genomic medicine product candidates, offer perspective on clinical data being presented at the upcoming American Society of Hematology Annual Meeting, and provide an overview of the Company’s manufacturing capabilities to support clinical and commercial supply.

A live webcast of the R&D Day including audio and slides will be available on the Events and Presentations page of the Sangamo website. A replay of the event will be archived on the website.

About Sangamo Therapeutics

Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and gene regulation. For more information about Sangamo, visit www.sangamo.com.

Sangamo Forward Looking Statements

This press release contains forward-looking statements regarding Sangamo’s current expectations. These forward-looking statements include, without limitation, statements regarding the Company’s ability to develop and commercialize product candidates to address genetic diseases with the Company’s proprietary technologies, as well as the timing of commencement of clinical programs and the anticipated benefits therefrom. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the outcomes of clinical trials, uncertainties related to clinical trials, and Sangamo’s reliance on partners to meet clinical and manufacturing obligations. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Sangamo and its partners will be able to develop commercially viable product candidates. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in Sangamo’s operations and business environments. These risks and uncertainties are described more fully in Sangamo’s Annual Report on Form 10-K for the year ended December 31, 2018 as filed with the Securities and Exchange Commission and Sangamo’s most recent Quarterly Report on Form 10-Q. Forward-looking statements contained in this announcement are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191206005067/en/

See also  End of the world: Why apocalyptic space event leaves Earth’s prospects ‘dim’ – Scientist

CONTACT: Investor Relations – Global

McDavid Stilwell

510-970-6000, x219

mstilwell@sangamo.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA NEW YORK

INDUSTRY KEYWORD: HEALTH MEDICAL DEVICES STEM CELLS GENETICS CLINICAL TRIALS PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: Sangamo Therapeutics, Inc.

Copyright Business Wire 2019.

PUB: 12/06/2019 08:30 AM/DISC: 12/06/2019 08:30 AM

http://www.businesswire.com/news/home/20191206005067/en





READ SOURCE

LEAVE A REPLY

Please enter your comment!
Please enter your name here